| Literature DB >> 35815311 |
Mengjie Xue1, Yuting Zhao1, Ying Cui1, Jing Yang1, Yuefei Wang1,2, Xin Chai1,2.
Abstract
Qufeng Zhitong capsule (QZC) is a well-known Chinese patent medicine that has been widely applied for the clinical treatment of rheumatoid arthritis and other inflammatory diseases. To date, its material basis is still unclear, which has greatly limited its clinical application. In this study, by taking advantage of ultra-high-performance liquid chromatography tandem Q-Exactive Orbitrap high-resolution mass spectrometry, 16 chemical components such as gallic acid, protocatechuic acid, and neochlorogenic acid in QZC were characterized and unambiguously identified based on comparison with the corresponding reference standards. In addition, the correlation between the focused components and their corresponding raw herbs from QZC prescription was investigated. For the first time, the relationship between the components mentioned above and their anti-inflammatory activity was explored via network pharmacology analysis, and a visualized network of "medicinal materials-QZC-compounds-targets-pathways" was established. Based on the brief prediction results of network pharmacological analysis, ultra-performance liquid chromatography coupled with photodiode array detector method was validated in terms of linearity, limit of detection, limit of quantification, precision, repeatability, stability, and recovery test and was successfully employed to determine 16 compounds in 28 batches of QZCs, which confirmed the feasibility and reliability of the established method for the quantitative analysis of 16 compounds in QZC. Considering the content and bioactivity of the tested components, four compounds were recommended as candidate indicators for quality evaluation ultimately. The potential value of this study could not only support a quality evaluation of QZC but also provide a theoretical basis for further in-depth research of QZC in clinical research.Entities:
Year: 2022 PMID: 35815311 PMCID: PMC9259231 DOI: 10.1155/2022/4229945
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.594
Characterization of chemical components from QZC by UHPLC/Q-Orbitrap-MS.
| Peak no. |
| Formula | ES+ ( | ES− ( | Identification | Source |
|---|---|---|---|---|---|---|
| 1 | 1.97 | C7H6O5 | — | 169.01329 | Gallic acid | HG |
| 2 | 3.93 | C7H6O4 | — | 153.0186 | Protocatechuic acid | HG |
| 3 | 5.84 | C16H18O9 | 355.10245 | 353.0878 | Neochlorogenic acid | RD, HV |
| 4 | 9.32 | C16H18O9 | 355.10239 | 353.08841 | Chlorogenic acid | RD, FC, HV |
| 5 | 10.63 | C16H18O9 | 355.10245 | 353.08762 | Cryptochlorogenic acid | RD, HV |
| 6 | 10.74 | C16H24O10 | — | 375.12973 | Loganic acid | RD |
| 7 | 12.92 | C27H22O18 | — | 633.07214 | Corilagin | HG |
| 8 | 15.42 | C18H28O12 | — | 435.15176 | Loganin | RD |
| 9 | 19.47 | C25H24O12 | — | 515.11908 | Isochlorogenic acid B | RD, ReRC |
| 10 | 19.91 | C25H24O12 | — | 515.11902 | Isochlorogenic acid A | RD |
| 11 | 22.6 | C25H24O12 | — | 515.11896 | Isochlorogenic acid C | RD |
| 12 | 26.3 | C20H24O7 | — | 377.15918 | Angelol A | RAP |
| 13 | 28.75 | C16H16O5 | 289.10638 | — | Columbianetin acetate | RAP |
| 14 | 32.22 | C47H76O18 | — | 973.50336 | Akebia saponin D | RD |
| 15 | 32.64 | C15H16O3 | 245.11714 | — | Osthole | RAP |
| 16 | 33.08 | C19H20O5 | 329.13821 | — | Columbianadin | RAP |
Compared with reference standards.
Figure 1Network pharmacological analysis of QZC: (a) KEGG network diagram, (b) PPI network, and (c) parallel coordinate plot for the medicinal materials-QZC-compounds-targets-pathways.
Figure 2Optimization of extraction conditions by “spider-web” for QZC.
Figure 3UPLC-PDA chromatograms: (a) the mixed standard solution acquired by wavelength switching mode; (b) AsD in the mixed standard solution at 211 nm; (c) QZC sample solution acquired by wavelength switching mode; (d) AsD in QZC sample solution at 211 nm. 1: Gaa; 2: Pra; 3: Nea; 4: Cha; 5: Cra; 6: Loa; 7: Cor; 8: Log; 9: IaB; 10: IaA; 11: IaC; 12: AnA; 13: Coa; 14: AsD; 15: Ost; 16: Col.
Linear regression, LoD and LoQ, intra- and interday precisions, repeatability, stability, and recovery for 16 compounds.
| Compound | Regression equation |
| Linear range ( | LoD ( | LoQ ( | Precision (RSD, %) | Repeatability (RSD, %; | Stability (RSD, %; | Recovery (mean ± SD, %; | |
|---|---|---|---|---|---|---|---|---|---|---|
| Intraday | Interday | |||||||||
| Gaa |
| 0.9998 | 3.111–199.1 | 0.1152 | 0.3457 | 0.3 | 1.6 | 1.6 | 0.5 | 96.5 ± 1.8 |
| Pra |
| >0.9999 | 0.1664–10.65 | 0.1664 | 0.3329 | 2.0 | 1.0 | 1.5 | 1.4 | 93.1 ± 2.4 |
| Nea |
| 0.9998 | 0.3793–24.28 | 0.04215 | 0.1264 | 1.7 | 1.2 | 0.9 | 2.4 | 95.3 ± 2.8 |
| Cha |
| 0.9998 | 0.9302–59.53 | 0.1034 | 0.3101 | 0.6 | 0.6 | 0.6 | 1.6 | 95.0 ± 1.6 |
| Cra |
| 0.9999 | 0.3795–24.29 | 0.1265 | 0.3795 | 2.6 | 2.9 | 0.7 | 2.4 | 97.3 ± 2.6 |
| Loa |
| >0.9999 | 4.240–271.4 | 0.1570 | 0.4711 | 0.9 | 0.9 | 1.1 | 0.4 | 92.8 ± 1.5 |
| Cor |
| 0.9999 | 1.335–85.44 | 0.1483 | 0.4450 | 0.4 | 1.4 | 2.0 | 0.3 | 99.1 ± 1.7 |
| Log |
| >0.9999 | 0.9607–61.48 | 0.1067 | 0.3202 | 0.3 | 1.0 | 2.8 | 0.5 | 97.8 ± 2.6 |
| IaB |
| >0.9999 | 0.3113–19.92 | 0.1038 | 0.3113 | 0.4 | 0.8 | 2.8 | 1.5 | 104.7 ± 2.6 |
| IaA |
| 0.9999 | 0.2183–13.97 | 0.07278 | 0.2183 | 0.6 | 2.4 | 2.3 | 1.2 | 108.2 ± 1.0 |
| IaC |
| 0.9994 | 0.3990–25.54 | 0.1330 | 0.3990 | 1.2 | 2.4 | 2.9 | 1.0 | 106.6 ± 3.1 |
| AnA |
| >0.9999 | 1.154–73.85 | 0.04274 | 0.1282 | 1.1 | 1.6 | 1.1 | 0.3 | 100.6 ± 1.1 |
| Coa |
| >0.9999 | 0.7836–50.15 | 0.02118 | 0.08707 | 0.4 | 1.4 | 1.0 | 0.2 | 103.0 ± 1.2 |
| Ost |
| >0.9999 | 1.357–86.86 | 0.05026 | 0.1508 | 0.4 | 1.0 | 1.0 | 0.1 | 107.6 ± 2.6 |
| Col |
| >0.9999 | 0.2003–12.82 | 0.06675 | 0.2003 | 1.4 | 2.4 | 1.3 | 1.3 | 102.4 ± 1.8 |
| AsD |
| >0.9999 | 17.28–1106 | 1.728 | 3.455 | 2.4 | 1.9 | 1.4 | 0.6 | 92.1 ± 1.5 |
Figure 4Heat map and box plot of 16 compounds in 28 batches of QZCs.